POKONZA (potassium chloride) by Ascentage Pharma is (k+) is the principal intracellular cation of most body tissues. First approved in 2014.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
POKONZA is an oral potassium chloride solution used to treat or prevent hypokalemia (low potassium levels). Potassium is the principal intracellular cation essential for nerve impulse transmission, muscle contraction, and renal function. The drug replaces depleted potassium to restore normal plasma concentrations (3.5–5 mEq/L).
Product is in peak lifecycle stage with stable commercial demand for a standard electrolyte replacement, supporting steady-state team operations.
(K+) is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
POKONZA offers stable, low-growth career opportunities in a mature therapeutic category with minimal pipeline expansion or competitive disruption. Roles focus on market maintenance, physician education, and customer relations rather than innovation or launch dynamics.
Worked on POKONZA at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo